Product Reports Resources Pricing Login Book a demo

argenx

Biotech & Life Sciences · Ghent, Belgium · Founded 2008 · IPO 2014

Platform for antibody lead choice that supports the discovery of human antibody therapeutics

Valuation $49B
Revenue $6.18B
EBITDA $2.01B

Investors

11 investors on argenx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
MVM Life Science Partners
Forbion Capital Partners
Omnes Capital
KBC
Thuja Capital
BioGeneration Ventures
Erasmus MC Biomedical Fund
Series B+ 4 investors entered at this stage
OrbiMed
EQT Life Sciences
PMV
Seventure Partners

Global footprint

Where argenx has talent and traffic

Workforce by country
28 countries with
team presence
🇺🇸 United States40.5%
🇧🇪 Belgium34.9%
🇬🇧 United Kingdom4.3%
🇨🇭 Switzerland2.6%
🇩🇪 Germany2.5%
Top 5 of 28 shown
Web traffic by country
63K monthly visits
across markets
🇺🇸 United States40%
🇧🇪 Belgium14.3%
🇬🇧 United Kingdom7.3%
🏳️ Korea4%
🏳️ Republic of3.2%
Top 5 markets shown

Talent graph

The shape of argenx's talent

Dealroom maps argenx's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

26 standout operatorsDealroom-flagged across the org
10 AI specialistspinpointed by name
2,278 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock argenx's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$198M patent portfolio · 81 active families

Estimated portfolio value
$198M
0.41% of market cap · larger than top peer RAPT Therapeutics ($28M)
81 active patent families
Where argenx innovates AntagonistAntiendomysial antibodiesAntigen bindingMolecular biologyAntigen Binding Fragment

Where argenx concentrates vs peers

Each axis is a top-10 topic across argenx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

argenx's 3 investments and acquisitions.

Every disclosed deal where argenx appeared as a backer or acquirer, 2019–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across argenx's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        argenx's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about argenx

        An AI-synthesized read of the highest-engagement posts about argenx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See argenx on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.